

November 13, 2024

BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. National Stock Exchange of India Limited Listing Department Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051.

Scrip code: 512529

Dear Sir/ Madam,

Symbol: SEQUENT

Subject: Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024.

Pursuant to Regulation 30 (read with Part A of Schedule III) we are enclosing herewith the Investor Presentation on Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2024.

Thanking you,

Yours faithfully, For **Sequent Scientific Limited**

Phillip Trott Company Secretary & Compliance Officer

Encl.: A/a

SeQuent Scientific Limited

Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra, India Tel No.: +91-22-4111-4777 I CIN: L99999MH1985PLC036685

Website: http://www.sequent.in | Email Id: investorrelations@sequent.in



INVESTOR PRESENTATION Q2 FY25

SEQUENT SCIENTIFIC LIMITED

14th Nov 2024



The quarter under review (Q2 FY25) is significant for two reasons. Firstly, we continue to strengthen our performance in all parts of the business. Secondly, we announced the merger of Sequent Scientific Limited and Viyash Life Sciences to build a unique, differentiated, end-to-end integrated global pharmaceuticals platform supported by strong operating and R&D backbone

Our Q2FY25 revenues grew by 6.6% Year-on-Year ("YoY") to Rs 3,686mn on the back of improved demand in key markets and expansion initiatives in formulations. This growth was on the back of a very strong performance in Formulations, where almost all markets grew in double digits. The API business had a flat quarter, while seeing continuing improvement on margins. When aggregated for the first half of the year, the overall revenue growth of the company is at 11.7 % YoY. Our gross margins have continued to trend upwards as we register the benefits of initiatives of cost improvement programs and superior portfolio mix. Our EBITDA (pre-esop costs) for the quarter of INR 447 Mn represents a 70% growth YoY, while the first half EBITDA (pre-esop) at Rs 930 Mn showed a growth of 161% YoY.

On September 26, 2024, we announced the proposal for a strategic merger with Viyash Life Sciences Private Limited ("Viyash"). The merger process is underway, and we expect to complete it in the next 12-15 months subject to regulatory approvals. We are also pleased to share that Viyash's first half performance is ahead of plan with 5.4% revenue growth YoY and 31% EBITDA growth YoY along with acceleration in new product introductions and R&D activities


We are now poised for accelerated growth while improving margins. With Viyash's strong end-to-end industry capabilities, this merger will significantly enhance SeQuent's scale, expand its capabilities, strengthen its supply chain, and position the combined entity as a dominant force in high-growth target markets

Rajaram Narayanan

Managing Director and CEO




SeQuent Q2FY25: Continued growth in Revenue and earnings J Sequent




SeQuent: H1FY25 - Continued growth in Revenue and earnings





SeQuent : Q2 FY25: Revenue Performance – by geography

All values in ₹ Mn




Provision for customer claim on shipments in prior years

- **Europe:** Volume growth and improved product mix (*Q1FY25 includes exceptional sale of vaccine*)
- **Emerging Markets:** Turkey sales growth is driven by recovery of volume losses and selective price increases
- India: Project Udaan (Geo-expansion) implemented. Some impact of discontinued portfolios remains
- API Spill over of sales from Q2 to Q3. Strong y-o-y revenue growth in the anthelmintic portfolio

*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

SeQuent Scientific Limited



facilities

SeQuent: Q2 FY25 Consolidated Financials



Particulars	Q2	Q2	Grw	Q1	Grw	H1	H1	Grw
	FY25	FY24	YoY %	FY25	QnQ %	FY25	FY24	YoY %
Revenue from Operations	3,686	3,460	7%	3,902	-6%	7,589	6,792	12%
Material Consumption	(1,953)	(1,898)	3%	(2,143)	-9%	(4,096)	(3,846)	7%
Gross Margin	1,734	1,562	11%	1,759	-1%	3,493	2,946	19%
%	47.0%	45.1%		45.1%		46.0%	43.4%	
Employee Benefit Expenses	(603)	(602)	0%	(579)	4%	(1,183)	(1,180)	0%
Operating Expenses	(683)	(697)	-2%	(697)	-2%	(1,380)	(1,410)	-2%
EBITDA (pre-ESOP)	447	263	70%	483	-7%	930	356	161%
%	12.1%	7.6%		12.4%		12.3%	5.2%	
ESOP cost	(67)	(62)		(41)		(108)	(126)	
EBITDA	380	201	89%	442	-14%	821	231	256%
%	10.3%	5.8%		11.3%		10.8%	3.4%	
Exceptional Items	(43)	81		-		(43)	(154)	
IndAS 29 Adjustment	25	(25)		(8)		17	(52)	
Exchange Gain / (Loss)	(14)	(25)		(14)		(28)	(110)	
Other Income	45	16		27		72	24	
Finance Cost	(143)	(126)		(164)		(307)	(231)	
Depreciation	(171)	(154)		(162)		(333)	(296)	
Earnings Before Tax	79	(31)	NM	120	-34%	199	(588)	NM
Taxes	(16)	(38)		(29)		(45)	172	
Earnings After Tax	63	(69)	NM	91	-30%	154	(416)	NM
Minority Interest	37	15		25		63	17	
Earnings after Minority Interest	26	(84)	NM	65	-60%	91	(432)	NM

Key Notes Q2 FY25 Y-o-Y :

+ 1.9% on YoY Gross
Margin improvement in Q2 FY25:
• Formulations: Ongoing advantages from portfolio initiatives in Europe and pricing adjustments in Turkey

•**API:** Cost and operational excellence initiatives under Project Pragati led to an expansion in margins

- Operating expenses decrease YoY (despite inflationary pressures) due to restructuring initiatives and operational efficiencies.
- Increase in finance cost on account of restructuring of debt arrangements.



Particulars	Sep-24	Mar-24*		
Shareholders' Funds	6,796	6,566		
Minority Interest	623	564		
Net Debt	3,774	3,788		
Investments	4	9		
Tangible Assets	3,060	3,112		
Intangible Assets	3,031	2,967		
Working Capital	4,442	4,201		

Che and


 Net Debt is maint 	tained
---------------------------------------	--------

• Working capital increase to support increased sales despatches planned for Turkey and Spain.




Viyash: Business Update

Viyash: Q2 FY25 – Strong quarterly performance with high growth, profitability improvement and reduction in net debt



Viyash


Viyash: H1 FY25 – Strong H1FY25 performance with revenue growth, improvement in profitability and reduction in net debt



Viyash


Key updates from H1FY25





Strong Business Profile





All values in ₹ Mn



Particulars	Q2	Q2	Grw YoY %	Q1	Grw QnQ %	H1	H1	Grw YoY %
	FY25	FY24		FY25		FY25	FY24 ²	
Revenue from Operations	3,632	3,300	10.1%	3,400	6.8%	7,032	6,671	5.4%
Material Consumption	(1,624)	(1,599)	1.6%	(1,580)	2.8%	(3,204)	(3,279)	-2.3%
Gross Profit	2,008	1,701	18.1%	1,820	10.3%	3,828	3,392	12.9%
%	55.3%	51.5%		53.5%		54.4%	50.8%	
Employee Benefit Expenses	(555)	(508)	9.3%	(547)	1.5%	(1,102)	(1,002)	9.9%
Other Operating Expenses	(841)	(779)	8.0%	(702)	19.8%	(1,543)	(1,481)	4.2%
Foreign Exchange Gain / (Loss)	17	57		9		26	17	
Adj. EBITDA ¹	628	471	33.4%	580	8.3%	1,208	925	30.6%
%	17.3%	14.3%		17.1%		17.2%	13.9%	

Note: 1. EBITDA for Viyash is adjusted for ESOP costs and call option charge (INR 217mn in Q2FY25 vs. INR 59mn in Q1FY25; Higher in Q2 due to accelerated vesting of warrants)

2. H2FY24 based on management accounts that have not been subject to limited review by auditors


Source: Viyash Life Sciences website published Investor Presentation

Merger Update



Q2FY25: Combined business performance






Notes: 1. EBITDA for Viyash is adjusted for ESOP costs, call option charge and includes Forex gains; EBITDA for SeQuent is adjusted for ESOP Costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

H1FY25: Combined business performance





Notes: 1. EBITDA for Viyash is adjusted for ESOP costs, call option charge and includes Forex gains; EBITDA for SeQuent is adjusted for ESOP Costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

Strong R&D, Superior Scale, Integrated Supply Chain, and Enhanced Front-end Presence








Merger will enable a unique, differentiated, and end-to-end integrated global animal health player

Multiple potential areas of synergies







Merger process status update

- We have filed with NSE and BSE and are currently addressing their queries
- Post NSE and BSE feedback, the Company will file with SEBI
- Post SEBI feedback, the Company will approach NCLT
- Pursuant to this, NCLT to call for shareholders' vote
- Other regulatory approvals, if any to follow

Expected timelines for the completion of the merger process as indicated before: 12-15 months (from merger announcement in September 2024)



Appendix





Combined P&L – Snapshot

Particulars	Viy	Viyash		SeQuent		Combined	
	FY24	H1FY25	FY24	H1FY25	FY24	H1FY25	
Revenue from Operations	13,110	7,032	13,697	7,589	26,807	14,621	
Material Consumption	(6,142)	(3,204)	(7,597)	(4,096)	(13,739)	(7,300)	
Gross Margin	6,968	3,828	6,100	3,493	13,068	7,321	
%	53.2%	54.4%	44.5%	46.0%	48.7%	50.1%	
Employee Benefit Expenses	(2,126)	(1,102)	(2,283)	(1,183)	(4,409)	(2,285)	
Operating Expenses	(3,206)	(1,543)	(2,748)	(1,380)	(5,954)	(2,923)	
Operating Exchange Gain / (Loss)	34	26	-	-	34	26	
Adjusted EBITDA	1,671	1,208	1,068	930	2,739	2,138	
%	12.7%	17.2%	7.8%	12.3%	10.2%	14.6%	
ESOP cost	(127)	(63)	(222)	(108)	(349)	(171)	
Exceptional Items ¹	(58)	(213)	(174)	(43)	(232)	(256)	
Ind AS 29 Adjustment	-	-	(78)	17	(78)	17	
Exchange Gain / (Loss)	-	-	(154)	(28)	(154)	(28)	
Other Income	502	89	110	72	612	161	
Finance Cost	(332)	(144)	(481)	(307)	(813)	(451)	
D&A	(718)	(353)	(539)	(297)	(1,257)	(650)	
Amortization of Acquisition Intangibles	(935)	(469)	(76)	(36)	(1,011)	(505)	
Profit Before Tax	3	54	(546)	199	(543)	253	
Taxes	(88)	(148)	250	(45)	162	(193)	
Profit After Tax	(85)	(94)	(296)	154	(381)	60	
Adjusted PAT ²	908	588	(46)	233	862	821	

1. Exceptional Items include cost of accelerated vesting for share warrants and call option charge (Viyash)

2. PAT adjusted for Amortization of acquisition intangibles and Exceptional Items

Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers



For details, feel free to contact:



Registered Office: 301/A, 'Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India Websites: <u>www.sequent.in</u>, <u>www.alivira.co</u> | CIN: L99999MH1985PLC036685 | BSE Code:512529 | NSE: SEQUENT | ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.